The AHA syposium was a huge success! Thanks for joining us.
MISSED THE EVENT? NOT A PROBLEM.
Each speaker is contributing to a post event CME monograph covering their symposium topics.
Look for yours in the mail soon!
Our expert program faculty discussed state-of-the-art evidence-based mangaement of stable and peripheral coronary artery disease:
PROGRAM CHAIRS and FACULTY:
Christopher B. Granger, MD (Chair) - Duke University Medical Center W. Brian Gibler, MD (Co-Chair) - President, EMCREG-International, University of Cincinnai
FACTOR Xa MECHANISM OF ACTION - IMPACT ON THE CLOTTING CASCADE, TISSUE FACTOR-INITIATED CLOTTING, INFLAMMATION, AND PLATELET ACTIVATION
Richard C. Becker, MD University of Cincinnati College of Medicine, Cincinnati, OH
DECREASING MAJOR ADVERSE CLINICAL EVENTS FOR PATIENTS WITH CORONARY ARTERY DISEASE AND PERIPHERAL ARTERY DISEASE: THE COMPASS TRIAL
Deepak L. Bhatt, MD, MPH Duke University Medical Center, Durham, NC
IMPROVING THE TREATMENT OF PERIPHERAL ARTERY DISEASE: PROVIDING INDIVIDUALIZED, INNOVATIVE, AND EFFICIENT CARE Manesh R. Patel, MD Duke University, Durham, NC
CLINICAL AND ECONOMIC VALUE OF RIVAROXABAN IN CORONARY ARTERY DISEASE Christopher B. Granger, MD Duke University Medical Center, Durham, NC
This monograph dicusses the use of high sensitivity troponin assays in patients presenting to the hospital with ACS from multiple perspectives including Emergency Medicine, Cardiology, Hospital Medicine, Laboratory Medicine, and Emergency Nursing. High sensitivity assays for troponin have been available for clinical use in Europe for the past decade and proved to be critical for the early diagnosis of acute myocardial necrosis in patients presenting to the emergency department (ED) with possible ACS and defining treatment for these patients which includes anti-platelet and anti-coagulant agents, as well as cardiologist intervention. In March 2017, high sensitivity cardiac troponin T was approved by the FDA for routine clinical use in the United States. Clearly many clinicians and laboratorians in the US have not had experience with high sensitivity troponin assays which has identified an important educational area for emphasis. This information on high sensitivity troponin becomes extremely important to emergency physicians, cardiologists, hospitalists, laboratorians, physician assistants, nurse practitioners, and emergency nurses as they routinely care for these often critically-ill patients.
Describe the use of high-sensitivity troponin assays with the integration of the multi-disciplinary team
Describe the evidence for high-sensitivity troponinassays in ACS
Describe the effectiveness of these assays when combined diagnostics algorithms like the HEART score
Discuss the importance of high-sensitivity troponin for the hospitalist as care is transitioned from the ED to the in-patient setting
Discuss the laboratory medicine perspective and the capabilities of the high sensitivity troponin assays
Discuss the critical role of emergency nurses, advanced practice nurses, and physician assistants in treating these patients with this exciting new technology
In this EMCREG-International Monograph, you will find a variety of cardiovascular articles which will hopefully be helpful to you in your practice of Emergency
Medicine and Acute Care Medicine. These manuscripts are based on the 2015 EMCREG-International Satellite Symposium which was held on October 25,
2015, during the 2015 ACEP Scientific Assembly in Boston, Massachusetts. The symposium and this Monograph entitled Optimal Therapy for Acute Coronary
Syndromes: Using Guideline-Based Treatments in the Emergency Setting explore multiple Acute Coronary Syndrome (ACS) topics which are extremely important
to emergency physicians, hospitalists, and other acute care providers such as physician assistants and nurse practitioners as they care for these often critically-ill
Identification of Patients with ACS in the ED at High Risk of Adverse Outcomes
2013 ACCF/AHA Guidelines for STEMI Patients
2014 ACCF/AHA Guideline for Treating Non-ST-Elevation ACS (NSTE ACS)
Challenges in Optimizing Antiplatelet Therapy for STEMI and NSTE ACS
Thromboelastography (TEG) Ė Understanding the Patientís Ability to Clot Blood
Optimizing Collaboration Between Emergency Physicians, Hospitalists, and Cardiologists for Treatment of ACS
COAGULATION CATASTROPHIES: TAKING CARE OF THE MOST DIFFICULT CASES IN EM
Join faculty experts, W. Brian Gibler, MD; James W. Hoekstra, MD; Charles Pollack, MD; E. Magnus Ohman, MD; Phillip Levy, MD; Jordon Bonomo, MD and Opeolu Adeoyeo, MD, as they review recent advances in cardiac biomarker diagnostics including high-sensitivity troponin assays and CT coronary angiography, novel anticoagulant therapy, advances in antiplatelet therapy which have been incorporated into the latest ACCF/AHA guidelines, the interventional cardiologists perspective, and novel diagnostics for determining a patientís clotting status by thromboelastography.
CARING FOR CRITICALLY ILL AND INJURED PATIENTS IN THE EMERGENCY DEPARTMENT
Join faculty experts as they review Emergency Physicians and Hospitalists care daily for patients who are critically ill and injured. The management of these patients is often complex and requires detailed diagnostic and therapeutic information, as well as a thorough understanding of disease pathophysiology. In this EMCREG-International Monograph, multiple critical care topics including critical respiratory illness/ventilator management, current therapy for septic shock, treatment of significant deep venous thrombosis and pulmonary embolism, management of atrial fibrillation, novel Factor Xa inhibitors and other antagonists to the clotting cascade, post-cardiac arrest resuscitation beyond hypothermia, and the use of thromboelastography to evaluate the patientís ability to clot blood. .